Abstract
To the Editor: Targeted therapy against epidermal growth factor receptors (EGFRs) has become standard of care for management of EGFR-mutated nonsmall cell lung cancer. Although these agents are associated with lower incidence of systemic side effects than traditional chemotherapy, they have a higher frequency of mucocutaneous side effects that severely impact quality of life and may lead to discontinuation of life-saving treatment.1 Since the onset of the eruption is soon after initiating EGFR therapy, identifying high-risk groups and starting prophylactic therapy early may prevent severe reactions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
